Bausch & Lomb (BLCO) EVP Hashad Yehia Receives Award of 20,973 Shares

What Happened
Hashad Yehia, EVP of R&D and Chief Medical Officer at Bausch & Lomb Corporation (BLCO), was awarded 20,973 common shares (reported as performance stock units, PSUs) on August 5, 2026. The Form 4 shows an acquisition at $0.00 per share (award), totaling $0 cash paid on grant. These PSUs satisfied the applicable performance conditions at the target (100%) as of August 5, 2026 and will convert to common shares if they vest on February 28, 2027, subject to continued employment.

Key Details

• Transaction date and price: 2026-08-05, Award (code A), 20,973 shares @ $0.00.
• Filing date: Form filed 2026-08-07 (appears filed within the typical 2-business-day window).
• Shares owned after transaction: Not disclosed in the provided filing details.
• Footnote: The award represents PSUs originally granted 02/28/2024 under the Bausch + Lomb 2022 Omnibus Incentive Plan; performance conditions were met at target (100%) as of 08/05/2026 (see F1). Vesting is scheduled for 02/28/2027 and is subject to continued employment.

Context
This was an earned equity award (performance-based PSU), not an open-market purchase or sale. Awards like this indicate incentive compensation tied to company performance and do not necessarily reflect immediate insider buying or selling intent. The shares are not yet vested and therefore are potential future common shares contingent on the vesting date and employment condition.